Notably, regorafenib treatment induced a near-complete tumor regression in the PRG4+ cohort, as by day 33 only one PRG4+ mouse had a detectable tumor mass of ∼1.5 mm as confirmed by IVIS imaging and subsequent histological analysis (Fig. 1C, F). The gene discussed is PRG4; the disease is neoplasm.